20 biotechnology companies on Sarat’s $100m shopping list

Biotechnology companies are what Sarat Investment says it wants to buy, not another fintech seed. The Saudi-linked investor has set out an aim to put 100 million dollars into 20 biotechnology companies. That is a target, not a closed fund announcement with a signed first close, a published portfolio or named cheques. Treat it as a mandate. Twenty names at 100 million dollars implies an average ticket near 5 million dollars, the size that usually buys a Series A sliver or a localisation round, not a manufacturing plant. That is the punch. Riyadh spent mid-September talking like a life-sciences capital. The Riyadh Global Medical Biotechnology Summit closed with more than 40 agreements the organisers valued above 5 billion riyals, and the Life Sciences Innovation Forum attached to it said investors had signalled more than 120 million dollars of interest across 23 pitching firms. Sarat’s 100 million dollar, 20-company line sits in that weather. It does not, on the public record reviewed here, equal those summit totals, and it should not be merged with them. Sarat is not a blank sheet. In September 2025, Sarat Ventures Y Innovations Biotech Fund, a UK vehicle anchored by Allocator One, launched with an anticipated 50 million dollars for early-stage firms tied to Saudi Arabia and the wider MENA region. General partners named at the time were Dr Megan Yung of Yung Ventures, part of Y Innovations Group, and Dr Huda Alfardus, previously linked to Healthgena. That vehicle was explicit about Vision 2030, a projected 11 to 12 billion dollar Saudi biotech market by 2030, and a path from lab to local market. Separately, Sarat Investments Holdings, chaired in coverage by Saud bin Abdulaziz Al-Saud, has appeared as a Kingdom-side investment holding with a large claimed asset base and project work with advisory firms. Whether the new 100 million dollar, 20-company aim is a doubling of the 2025 fund, a parallel book or a holding-company programme was not spelled out in a full term sheet attached to this brief. The Kingdom already has other biotech cheques on the table. IB Ventures launched with 50 million dollars. Lifera, backed by the Public Investment Fund, is building manufacturing. A BioLabs-linked accelerator took a first cohort that included names such as Plansulin, SAGEbio and Novo Genomics. Vaccine Industrial Company has been building a large human-vaccine site. National strategy language still points at a much larger 2040 GDP contribution from biotechnology. Capital is arriving. Molecules are slower. The MENA angle is import substitution with a term sheet. Gulf health systems buy a lot of science that is invented elsewhere. A 100 million dollar book aimed at 20 biotechnology companies is a bet that some of those firms will open a Riyadh lab, run a trial under a Saudi ethics board, or fill a vial in a local plant. That is different from listing a fund in London and hoping LPs like the story. It is also different from PIF-scale manufacturing. Twenty small positions can miss if none of them get a licence to sell. Caveats should travel with the 100 million dollars. Aim is not assets under management. Twenty companies have not been listed here. Diligence cycles in biotech run longer than a SaaS seed. A 5 million dollar average cheque will not build a fill-finish line. If this is the 2025 Sarat Ventures vehicle restated at a higher number, say so in the next release. If it is new dry powder, publish the first close and the first two term sheets. If Sarat writes the first five cheques into firms that actually open in the Kingdom, the 20-company target becomes a portfolio. If the number stays on a slide next to summit banners, it was a headline in a loud week. Count signed investments, not intended ones.